Literature DB >> 9276386

Comparison of screening methods for detection of extended-spectrum beta-lactamases and their prevalence among blood isolates of Escherichia coli and Klebsiella spp. in a Belgian teaching hospital.

E Vercauteren1, P Descheemaeker, M Ieven, C C Sanders, H Goossens.   

Abstract

Using a set of 33 well-defined extended-spectrum beta-lactamase (ESBL)-producing strains of Escherichia coli and Klebsiella pneumoniae, we compared three screening methods for ESBL detection: (i) a double-disk synergy test, (ii) a three-dimensional test (both the double-disk synergy test and the three-dimensional test were performed with ceftriaxone, ceftazidime, aztreonam, and cefepime), and (iii) the Etest ESBL screen (AB Biodisk, Solna, Sweden), based on the recognition of a reduction in the ceftazidime MIC in the presence of clavulanic acid. In the double-disk test, all four indicator antibiotics scored equally and 31 of the 33 reference strains were recognized. In the three-dimensional test, ceftriaxone was the only satisfactory indicator and 30 ESBL-positive strains were detected by this antibiotic. Both systems produced two false-positive results with cefepime. With the Etest ESBL screen, 15 of 16 TEM-related and 11 of 16 SHV-related ESBL-producing strains scored positive. In 10 cases the clavulanic acid on one end of the strip interfered with the MIC determination for ceftazidime, which was read on the opposite end. This MIC had to be determined with an extra ceftazidime-only strip. No false-positive results were noted. Eighty-six blood isolates of E. coli and Klebsiella species were screened for ESBL expression by the double-disk and three-dimensional tests, both with ceftriaxone. Six strains with suspicious antibiogram phenotypes also gave positive results by the double-disk test. One E. coli strain remained undetected by the three-dimensional test. Identification of the enzymes suspected of being ESBLs by isoelectric focusing (all strains) and DNA sequencing (1 strain) confirmed the screening test results except for one Klebsiella oxytoca strain, which proved to be a hyperproducer of its chromosomal enzyme and which also had a negative Etest score. The five true ESBL producers were all confirmed by the Etest ESBL screen. Pulsed-field gel electrophoresis proved that the E. coli strains were unrelated, but that two of the three K. pneumoniae strains were closely related.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9276386      PMCID: PMC229938          DOI: 10.1128/jcm.35.9.2191-2197.1997

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  23 in total

Review 1.  More extended-spectrum beta-lactamases.

Authors:  G A Jacoby; A A Medeiros
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

Review 2.  Extended-spectrum beta-lactamases.

Authors:  A Philippon; R Labia; G Jacoby
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

3.  Specific synthesis of DNA in vitro via a polymerase-catalyzed chain reaction.

Authors:  K B Mullis; F A Faloona
Journal:  Methods Enzymol       Date:  1987       Impact factor: 1.600

4.  Extended broad-spectrum beta-lactamases conferring transferable resistance to newer beta-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns.

Authors:  V Jarlier; M H Nicolas; G Fournier; A Philippon
Journal:  Rev Infect Dis       Date:  1988 Jul-Aug

5.  Nucleotide sequence of the ampicillin resistance gene of Escherichia coli plasmid pBR322.

Authors:  J G Sutcliffe
Journal:  Proc Natl Acad Sci U S A       Date:  1978-08       Impact factor: 11.205

6.  Characterization of beta-lactamases in situ on polyacrylamide gels.

Authors:  C C Sanders; W E Sanders; E S Moland
Journal:  Antimicrob Agents Chemother       Date:  1986-12       Impact factor: 5.191

7.  Evolution of plasmid-coded resistance to broad-spectrum cephalosporins.

Authors:  C Kliebe; B A Nies; J F Meyer; R M Tolxdorff-Neutzling; B Wiedemann
Journal:  Antimicrob Agents Chemother       Date:  1985-08       Impact factor: 5.191

8.  Transferable resistance to third-generation cephalosporins in clinical isolates of Klebsiella pneumoniae: identification of CTX-1, a novel beta-lactamase.

Authors:  D Sirot; J Sirot; R Labia; A Morand; P Courvalin; A Darfeuille-Michaud; R Perroux; R Cluzel
Journal:  J Antimicrob Chemother       Date:  1987-09       Impact factor: 5.790

9.  A new plasmidic cefotaximase in a clinical isolate of Escherichia coli.

Authors:  A Bauernfeind; H Grimm; S Schweighart
Journal:  Infection       Date:  1990 Sep-Oct       Impact factor: 3.553

10.  Detection of extended-spectrum beta-lactamase (ESBL)-producing strains by the Etest ESBL screen.

Authors:  M G Cormican; S A Marshall; R N Jones
Journal:  J Clin Microbiol       Date:  1996-08       Impact factor: 5.948

View more
  27 in total

1.  Ability of the VITEK 2 advanced expert system To identify beta-lactam phenotypes in isolates of Enterobacteriaceae and Pseudomonas aeruginosa.

Authors:  C C Sanders; M Peyret; E S Moland; C Shubert; K S Thomson; J M Boeufgras; W E Sanders
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

Review 2.  Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat.

Authors:  P A Bradford
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

3.  Evaluation of the Etest ESBL and the BD Phoenix, VITEK 1, and VITEK 2 automated instruments for detection of extended-spectrum beta-lactamases in multiresistant Escherichia coli and Klebsiella spp.

Authors:  Maurine A Leverstein-van Hall; Ad C Fluit; Armand Paauw; Adrienne T A Box; Sylvain Brisse; Jan Verhoef
Journal:  J Clin Microbiol       Date:  2002-10       Impact factor: 5.948

4.  Detection of extended-spectrum beta-lactamases among Enterobacteriaceae by use of semiautomated microbiology systems and manual detection procedures.

Authors:  Irith Wiegand; Heinrich K Geiss; Dietrich Mack; Enno Stürenburg; Harald Seifert
Journal:  J Clin Microbiol       Date:  2007-02-07       Impact factor: 5.948

5.  Biochemical characterization of the TEM-107 extended-spectrum β-lactamase in a Klebsiella pneumoniae isolate from South Korea.

Authors:  Kyungwon Lee; Jong Hwa Yum; Dongeun Yong; Seok Hoon Jeong; Gian Maria Rossolini; Jean-Denis Docquier; Yunsop Chong
Journal:  Antimicrob Agents Chemother       Date:  2011-09-12       Impact factor: 5.191

6.  Phylogenetic groups among Klebsiella pneumoniae isolates from Brazil: relationship with antimicrobial resistance and origin.

Authors:  Maíra Espíndola Silva de Melo; Adriane Borges Cabral; Maria Amélia Vieira Maciel; Vera Magalhães da Silveira; Ana Catarina de Souza Lopes
Journal:  Curr Microbiol       Date:  2011-02-25       Impact factor: 2.188

7.  Evaluation of the current National Committee for Clinical Laboratory Standards guidelines for screening and confirming extended-spectrum beta-lactamase production in isolates of Escherichia coli and Klebsiella species from bacteremic patients.

Authors:  O T Katz; N Peled; P Yagupsky
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-10-08       Impact factor: 3.267

8.  Molecular epidemiology of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae isolates in a district hospital in Taiwan.

Authors:  P Y Liu; J C Tung; S C Ke; S L Chen
Journal:  J Clin Microbiol       Date:  1998-09       Impact factor: 5.948

9.  Can results obtained with commercially available MicroScan microdilution panels serve as an indicator of beta-lactamase production among escherichia coli and Klebsiella isolates with hidden resistance to expanded-spectrum cephalosporins and aztreonam?

Authors:  E S Moland; C C Sanders; K S Thomson
Journal:  J Clin Microbiol       Date:  1998-09       Impact factor: 5.948

Review 10.  Extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae: considerations for diagnosis, prevention and drug treatment.

Authors:  Mark E Rupp; Paul D Fey
Journal:  Drugs       Date:  2003       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.